Navigation Links
Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
Date:11/12/2007

PARIS, November 12 /PRNewswire/ -- Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, today announced that Bristol-Myers Squibb Company (NYSE: BMY) has renewed its license to Aureus' AurSCOPE GPCR, and has also licensed Aureus' AurSCOPE Kinase and Ion Channel Knowledge databases.

Aureus Pharma's target-family-based AurSCOPE knowledge databases contain quantitative biological activity data which has been mined from the scientific literature. By understanding existing structure activity relationships, and the overall pharmacological space associated with a target/ligand, researchers can better design and prioritize experiments.

"We are very pleased that Bristol-Myers Squibb has chosen Aureus Pharma as a partner for knowledge based drug discovery," commented Jason Theodosiou, CEO of Aureus Pharma. "Bristol-Myers Squibb has been an important customer since 2002 and we regard their renewal and license extension as confirmation that our knowledge database solutions are meeting the needs of the world's leading pharmaceutical companies."

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus accelerates drug discovery by providing knowledge databases which contain high quality quantitative information for both chemistry and biology. Researchers gain rapid access to knowledge for important drug target classes including GPCR, Ion Channel, Kinase as well as other critical pharma topics including ADME/Drug-Drug Interactions and the hERG Channel. The data contained in the Aureus Pharma system is of importance to aid in lead discovery and optimization as well as to build predictive models. For further information on how Aureus helps researchers turn data into discovery visit http://www.aureus-pharma.com

Media Contact:

For Aureus Pharma:

Mary E. Donlan, Ph.D

Director of Sales & Marketing

+33-1-40-18-57-59/+33-6-76-19-51-77

mary.donlan@aureus-pharma.com


'/>"/>
SOURCE Aureus Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA)
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):